Condition: Vitiligo · Sponsor: Forte Biosciences, Inc.
A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients with Non-Segmental Vitiligo.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Skin & Cancer Foundation Australia - The Skin Hospital | Darlinghurst, New South Wales, Australia | Recruiting |
| Novatrials | Kotara, New South Wales, Australia | Recruiting |
| Cornerstone Dermatology | Coorparoo, Queensland, Australia | Recruiting |
| Optimal Clinical Trials North | Auckland, Auckland, New Zealand | Recruiting |
| Optimal Clinical Trials Central | Auckland, Auckland, New Zealand | Recruiting |
| Momentum Pukehoke | Auckland, Auckland, New Zealand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06905873